Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT
Authors
Keywords
Affibody, HER2-receptor, Shedding, PET, SPECT, T/R
Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 44, Issue 8, Pages 1337-1346
Publisher
Springer Nature
Online
2017-03-06
DOI
10.1007/s00259-017-3650-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT
- (2016) G. A. Ulaner et al. JOURNAL OF NUCLEAR MEDICINE
- Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT
- (2016) Jens Sörensen et al. Theranostics
- 123I-MIBG SPECT for Evaluation of Patients with Heart Failure
- (2015) A. C. Dimitriu-Leen et al. JOURNAL OF NUCLEAR MEDICINE
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule
- (2014) J. Sorensen et al. JOURNAL OF NUCLEAR MEDICINE
- Multicenter trials using 18F-fluorodeoxyglucose (FDG) PET to predict chemotherapy response: Effects of differential measurement error and bias on power calculations for unselected and enrichment designs
- (2013) Brenda F Kurland et al. Clinical Trials
- Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events
- (2013) E. Karlsson et al. EUROPEAN JOURNAL OF CANCER
- A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases
- (2013) Gaetano Aurilio et al. EUROPEAN JOURNAL OF CANCER
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Imaging EGFR and HER2 by PET and SPECT: A Review
- (2013) Emily B. Corcoran et al. MEDICINAL RESEARCH REVIEWS
- The ErbB/HER family of protein-tyrosine kinases and cancer
- (2013) Robert Roskoski PHARMACOLOGICAL RESEARCH
- When to order a biopsy to characterise a metastatic relapse in breast cancer
- (2012) T. Foukakis et al. ANNALS OF ONCOLOGY
- Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2012) Javier Cortés et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
- (2012) Linda Sofie Lindström et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis
- (2011) Nehmat Houssami et al. BREAST CANCER RESEARCH AND TREATMENT
- Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours
- (2011) Jaap J M Teunissen et al. ENDOCRINE-RELATED CANCER
- HER2 status in a population-derived breast cancer cohort: discordances during tumor progression
- (2010) Ulla Wilking et al. BREAST CANCER RESEARCH AND TREATMENT
- Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
- (2010) E C Dijkers et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications
- (2010) J. Löfblom et al. FEBS LETTERS
- Design of an Optimized Scaffold for Affibody Molecules
- (2010) Joachim Feldwisch et al. JOURNAL OF MOLECULAR BIOLOGY
- Targeting of HER2-Expressing Tumors Using 111In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold
- (2010) S. Ahlgren et al. JOURNAL OF NUCLEAR MEDICINE
- Structural basis for high-affinity HER2 receptor binding by an engineered protein
- (2010) C. Eigenbrot et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Methodological considerations in quantification of oncological FDG PET studies
- (2009) Dennis Vriens et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now